2022
Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies
Khera R, Schuemie MJ, Lu Y, Ostropolets A, Chen R, Hripcsak G, Ryan PB, Krumholz HM, Suchard MA. Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies. BMJ Open 2022, 12: e057977. PMID: 35680274, PMCID: PMC9185490, DOI: 10.1136/bmjopen-2021-057977.Peer-Reviewed Original ResearchConceptsLarge-scale Evidence GenerationType 2 diabetes mellitusCardiovascular effectivenessDiabetes mellitusSafety outcomesGlucagon-like peptide-1 receptor agonistsSodium-glucose co-transporter-2 inhibitorsMajor adverse cardiovascular eventsNew-user cohort designPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsSafety studiesAdverse cardiovascular eventsPrimary cardiovascular outcomePeptidase-4 inhibitorsAnti-hyperglycaemic agentsElectronic health record data sourcesEvidence generationCardiovascular eventsCardiovascular outcomesCardiovascular riskActive comparatorTherapeutic optionsReceptor agonistDrug comparisonsA prospective cohort study examining exposure to incarceration and cardiovascular disease (Justice-Involved Individuals Cardiovascular Disease Epidemiology – JUSTICE study): a protocol paper
Howell BA, Puglisi LB, Aminawung J, Domingo KB, Elumn J, Gallagher C, Horton N, Kazi DS, Krumholz HM, Lin HJ, Roy B, Wang EA. A prospective cohort study examining exposure to incarceration and cardiovascular disease (Justice-Involved Individuals Cardiovascular Disease Epidemiology – JUSTICE study): a protocol paper. BMC Public Health 2022, 22: 331. PMID: 35172807, PMCID: PMC8848673, DOI: 10.1186/s12889-022-12688-x.Peer-Reviewed Original ResearchConceptsCardiovascular risk factorsProspective cohort studyRisk factorsCardiovascular diseaseCardiovascular riskCohort studyCVD riskPsychosocial factorsCVD risk factor controlRisk factor controlClinical risk factorsTraditional risk factorsHealth care useIncarceration exposureIndex releaseCVD morbidityCVD incidenceJail/prisonCare useDiscussionOur studyLeading causeClinical measuresPsychosocial stressEpidemiology studiesProtocol paper
2021
Contemporary National Patterns of Eligibility and Utilization of Novel Cardioprotective Anti‐hyperglycemic agents in Type 2 Diabetes
Nargesi AA, Jeyashanmugaraja GP, Desai N, Lipska K, Krumholz H, Khera R. Contemporary National Patterns of Eligibility and Utilization of Novel Cardioprotective Anti‐hyperglycemic agents in Type 2 Diabetes. Journal Of The American Heart Association 2021, 10: e021084. PMID: 33998258, PMCID: PMC8403287, DOI: 10.1161/jaha.121.021084.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiomarkersBlood GlucoseCardiovascular DiseasesDiabetes Mellitus, Type 2Drug UtilizationEligibility DeterminationFemaleGlucagon-Like Peptide-1 ReceptorGuideline AdherenceHeart Disease Risk FactorsHumansIncretinsMaleMiddle AgedNutrition SurveysPractice Guidelines as TopicPractice Patterns, Physicians'Risk AssessmentSodium-Glucose Transporter 2 InhibitorsTime FactorsTreatment OutcomeUnited StatesConceptsSGLT-2 inhibitorsType 2 diabetes mellitusAtherosclerotic cardiovascular diseaseChronic kidney diseaseLarge clinical trialsGLP-1RAsDiabetes mellitusCardiovascular diseaseHeart failureKidney diseaseClinical trialsHigh-risk atherosclerotic cardiovascular diseaseGLP-1RA useAmerican Diabetes AssociationNutrition Examination SurveyAnti-hyperglycemic agentsPublic health benefitsComplex survey designCardiovascular riskGuideline recommendationsDiabetes AssociationExamination SurveyProtective therapyNational HealthAmerican College
2020
Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses
Wallach JD, Wang K, Zhang AD, Cheng D, Grossetta Nardini HK, Lin H, Bracken MB, Desai M, Krumholz HM, Ross JS. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. The BMJ 2020, 368: l7078. PMID: 32024657, PMCID: PMC7190063, DOI: 10.1136/bmj.l7078.Peer-Reviewed Original ResearchConceptsIndividual patient-level dataCardiovascular related deathsCardiovascular riskMyocardial infarctionRelated deathsSummary-level dataHeart failureOdds ratioSystematic reviewIncreased cardiovascular riskMore myocardial infarctionsHeart failure eventsCochrane Central RegistryAcute myocardial infarctionMyocardial infarction eventsPatient-level dataRandom-effects modelWeb of ScienceAnalysis of trialsEligible trialsComposite outcomeAdverse eventsContinuity correctionControlled TrialsRosiglitazone treatment
2019
Characteristics of High Cardiovascular Risk in 1.7 Million Chinese Adults.
Lu J, Lu Y, Yang H, Bilige W, Li Y, Schulz W, Masoudi FA, Krumholz HM. Characteristics of High Cardiovascular Risk in 1.7 Million Chinese Adults. Annals Of Internal Medicine 2019, 170: 298-308. PMID: 30776800, DOI: 10.7326/m18-1932.Peer-Reviewed Original ResearchConceptsHigh CVD riskCVD riskHigh riskHigh cardiovascular disease riskCardiovascular risk increasesHigh cardiovascular riskOverall study populationCardiovascular disease riskBody mass indexMultivariable mixed modelsNational Health CommissionAntihypertensive medicationsAspirin useCardiovascular riskCVD screeningMass indexStudy populationChinese adultsHan ethnicityDisease riskStatinsMixed modelsHealth CommissionSocioeconomic statusPopulation subgroups
2018
Implications of coronary artery calcium testing on risk stratification for lipid-lowering therapy according to the 2016 European Society of Cardiology recommendations: The MESA study
Bittencourt MS, Blankstein R, Blaha MJ, Sandfort V, Agatston AS, Budoff MJ, Blumenthal RS, Krumholz HM, Nasir K. Implications of coronary artery calcium testing on risk stratification for lipid-lowering therapy according to the 2016 European Society of Cardiology recommendations: The MESA study. European Journal Of Preventive Cardiology 2018, 25: 1887-1898. PMID: 30043629, DOI: 10.1177/2047487318788930.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkersClinical Decision-MakingCoronary AngiographyCoronary Artery DiseaseDyslipidemiasFemaleHumansHypolipidemic AgentsIncidenceLipidsMaleMiddle AgedPractice Guidelines as TopicPredictive Value of TestsPrognosisProspective StudiesRisk AssessmentRisk FactorsUnited StatesVascular CalcificationConceptsLipid-lowering treatmentCoronary artery calciumLipid-lowering therapyArtery calciumHigher cardiovascular mortalityCardiovascular mortalityUncontrolled groupCoronary Artery Calcium TestingCoronary heart disease eventsEuropean SocietyHeart disease eventsCardiovascular mortality ratesCardiovascular risk assessmentLow-risk groupCardiology recommendationsCardiology guidelinesCardiovascular riskESC recommendationsRisk stratificationMESA participantsCalcium testingRisk groupsGroup 31Lower incidenceMESA studyAccurate estimation of cardiovascular risk in a non-diabetic adult: detecting and correcting the error in the reported Framingham Risk Score for the Systolic Blood Pressure Intervention Trial population
Warner F, Dhruva SS, Ross JS, Dey P, Murugiah K, Krumholz HM. Accurate estimation of cardiovascular risk in a non-diabetic adult: detecting and correcting the error in the reported Framingham Risk Score for the Systolic Blood Pressure Intervention Trial population. BMJ Open 2018, 8: e021685. PMID: 30037874, PMCID: PMC6059296, DOI: 10.1136/bmjopen-2018-021685.Peer-Reviewed Original ResearchConceptsSystolic Blood Pressure Intervention TrialFramingham risk scoreCardiovascular riskRisk scoreStudy populationStudy participantsNon-diabetic adultsTotal study populationHigh-risk populationClinical trial dataClinical trial sitesTrial populationIntervention trialsRisk populationsNew England JournalIndependent investigatorsTrial dataSecondary analysisSPRINT trialSPRINT dataTrialsRiskScoresParticipantsPopulation
2016
Editor’s Choice-Sex differences in young patients with acute myocardial infarction: A VIRGO study analysis
Bucholz EM, Strait KM, Dreyer RP, Lindau ST, D’Onofrio G, Geda M, Spatz ES, Beltrame JF, Lichtman JH, Lorenze NP, Bueno H, Krumholz HM. Editor’s Choice-Sex differences in young patients with acute myocardial infarction: A VIRGO study analysis. European Heart Journal Acute Cardiovascular Care 2016, 6: 610-622. PMID: 27485141, PMCID: PMC5459677, DOI: 10.1177/2048872616661847.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionMyocardial infarctionYoung womenTime of AMIST-segment elevation myocardial infarctionHigh clinical risk scoreSegment elevation myocardial infarctionChronic obstructive pulmonary diseaseYoung AMI patientsCardiovascular risk factorsClinical risk scorePre-hospital delayProspective cohort studyCongestive heart failureElevation myocardial infarctionObstructive pulmonary diseaseHigh-risk populationYoung menMental health statusElectrocardiogram findingsMorbid obesityCardiovascular riskCohort studyRenal failureYounger patients
2015
Depressive Symptoms in Younger Women and Men With Acute Myocardial Infarction: Insights From the VIRGO Study
Smolderen KG, Strait KM, Dreyer RP, D'Onofrio G, Zhou S, Lichtman JH, Geda M, Bueno H, Beltrame J, Safdar B, Krumholz HM, Spertus JA. Depressive Symptoms in Younger Women and Men With Acute Myocardial Infarction: Insights From the VIRGO Study. Journal Of The American Heart Association 2015, 4: e001424. PMID: 25836055, PMCID: PMC4579927, DOI: 10.1161/jaha.114.001424.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionDepressive symptomsLifetime historyMyocardial infarctionRisk factorsYoung acute myocardial infarctionYoung AMI Patients (VIRGO) studyMore cardiovascular risk factorsYoung womenCardiovascular risk factorsTime of admissionAdverse medical outcomesMore depressive symptomsLow socioeconomic profileAMI severityVIRGO StudyCardiovascular riskChart abstractionYounger patientsClinical profileRelevant sex differencesPatient profilesAMI admissionsMedical outcomesPatientsSymptom Recognition and Healthcare Experiences of Young Women With Acute Myocardial Infarction
Lichtman JH, Leifheit-Limson EC, Watanabe E, Allen NB, Garavalia B, Garavalia LS, Spertus JA, Krumholz HM, Curry LA. Symptom Recognition and Healthcare Experiences of Young Women With Acute Myocardial Infarction. Circulation Cardiovascular Quality And Outcomes 2015, 8: s31-s38. PMID: 25714826, PMCID: PMC4801001, DOI: 10.1161/circoutcomes.114.001612.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsConflict, PsychologicalFemaleHealth Knowledge, Attitudes, PracticeHealth Status DisparitiesHealthcare DisparitiesHospitalizationHumansInterviews as TopicMiddle AgedMyocardial InfarctionPatient Acceptance of Health CarePreventive Health ServicesQualitative ResearchRecognition, PsychologyRisk AssessmentRisk FactorsSex FactorsTime FactorsTime-to-TreatmentConceptsAcute myocardial infarctionCare-seeking behaviorAcute careMyocardial infarctionProdromal symptomsHeart diseaseSymptom recognitionAcute myocardial infarction symptomsAcute myocardial infarction mortalityHealthcare systemMyocardial infarction symptomsPreventive health careCare-seeking experiencesMyocardial infarction mortalityAcute medical therapyPreventive health behaviorsCardiovascular riskMedical therapyPrompt recognitionPreventive carePrimary careInfarction symptomsAged menMortality riskHealth behaviors
2014
Descriptions and Interpretations of the ACCORD-Lipid Trial in the News and Biomedical Literature: A Cross-Sectional Analysis
Downing NS, Cheng T, Krumholz HM, Shah ND, Ross JS. Descriptions and Interpretations of the ACCORD-Lipid Trial in the News and Biomedical Literature: A Cross-Sectional Analysis. JAMA Internal Medicine 2014, 174: 1176-1182. PMID: 24796406, PMCID: PMC4124903, DOI: 10.1001/jamainternmed.2014.1371.Peer-Reviewed Original ResearchConceptsACCORD lipid trialACCORD-LipidFibrate useTrial interpretationImproved cardiovascular outcomesCross-sectional studyCross-sectional analysisStatin therapyCardiovascular outcomesCardiovascular riskDiabetes (ACCORD) trialDiabetes mellitusConflicts of interestTrialsPatientsFenofibrateAuthor conflictsLipid componentsMellitusTherapyPhysiciansMonths
2013
Target cardiovascular risk rather than cholesterol concentration
Krumholz HM. Target cardiovascular risk rather than cholesterol concentration. The BMJ 2013, 347: f7110. PMID: 24284344, DOI: 10.1136/bmj.f7110.Peer-Reviewed Original Research
2012
Loneliness and Living Alone: Comment on “Loneliness in Older Persons” and “Living Alone and Cardiovascular Risk in Outpatients at Risk of or With Atherothrombosis”
Bucholz EM, Krumholz HM. Loneliness and Living Alone: Comment on “Loneliness in Older Persons” and “Living Alone and Cardiovascular Risk in Outpatients at Risk of or With Atherothrombosis”. JAMA Internal Medicine 2012, 172: 1084-1085. PMID: 22710997, PMCID: PMC3670596, DOI: 10.1001/archinternmed.2012.2649.Peer-Reviewed Original Research
2011
Use of Fibrates in the United States and Canada
Jackevicius CA, Tu JV, Ross JS, Ko DT, Carreon D, Krumholz HM. Use of Fibrates in the United States and Canada. JAMA 2011, 305: 1217-1224. PMID: 21427374, PMCID: PMC3332101, DOI: 10.1001/jama.2011.353.Peer-Reviewed Original ResearchMeSH KeywordsCanadaCardiovascular DiseasesCohort StudiesCosts and Cost AnalysisDiabetes Mellitus, Type 2Drug CostsDrugs, GenericFenofibrateFibric AcidsHealth ExpendituresHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsMedical AuditPractice Patterns, Physicians'PrescriptionsUnited StatesConceptsUse of fibratesRole of fibratesObservational cohort studyIMS Health dataFenofibrate useCardiovascular riskCohort studyDiabetes (ACCORD) trialClinical benefitFibratesMonthsPrescriptionUnited StatesPatientsNegative resultsFenofibrateHealth dataCurrent useGeneric formulationPopulationStatinsTherapyTrials
2010
A Perspective on the American Heart Association/American College of Cardiology Science Advisory on Thiazolidinedione Drugs and Cardiovascular Risks
Krumholz HM. A Perspective on the American Heart Association/American College of Cardiology Science Advisory on Thiazolidinedione Drugs and Cardiovascular Risks. Circulation Cardiovascular Quality And Outcomes 2010, 3: 221-222. PMID: 20181986, DOI: 10.1161/circoutcomes.110.936070.Peer-Reviewed Original Research
2009
Determinants of Cardiac Catheterization Use in Older Medicare Patients With Acute Myocardial Infarction
Ko DT, Ross JS, Wang Y, Krumholz HM. Determinants of Cardiac Catheterization Use in Older Medicare Patients With Acute Myocardial Infarction. Circulation Cardiovascular Quality And Outcomes 2009, 3: 54-62. PMID: 20123672, PMCID: PMC3024143, DOI: 10.1161/circoutcomes.109.858456.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overCardiac CatheterizationChi-Square DistributionComorbidityFemaleHemorrhageHospitalizationHumansLikelihood FunctionsLogistic ModelsMaleMedicareMyocardial InfarctionPatient SelectionPractice Patterns, Physicians'Risk AssessmentRisk FactorsSeverity of Illness IndexSex FactorsTime FactorsTreatment OutcomeUnited StatesConceptsAcute myocardial infarctionCardiac catheterization useCardiac catheterizationInappropriate indicationsAMI patientsAppropriate indicationsMyocardial infarctionRisk scoreCardiology/American Heart Association class IBaseline cardiovascular riskOlder Medicare patientsHigh-risk patientsDemographic factorsMore comorbiditiesCardiovascular riskOlder patientsMale sexProcedure indicationFemale sexMedicare patientsAmerican CollegeAMI admissionsMedicare feePatientsCatheterizationPooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance
Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM. Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance. JAMA Internal Medicine 2009, 169: 1976-1985. PMID: 19933959, PMCID: PMC2830805, DOI: 10.1001/archinternmed.2009.394.Peer-Reviewed Original ResearchMeSH KeywordsAdverse Drug Reaction Reporting SystemsCardiovascular SystemCyclooxygenase 2 InhibitorsDrug IndustryHumansIncidenceLactonesMyocardial InfarctionRandomized Controlled Trials as TopicRisk AssessmentSafety-Based Drug WithdrawalsSulfonesTime FactorsUnited StatesUnited States Food and Drug AdministrationConceptsPlacebo-controlled trialVoluntary market withdrawalAdverse eventsCardiovascular riskThromboembolic adverse eventsMain outcome measurementsClinical trial dataRofecoxib groupOutcome measurementsTrial dataPlaceboTrial durationSafety surveillanceTrialsMarket withdrawalDeathRiskP-valueSurveillance effortsSubjectsWithdrawalRofecoxibYearsIncidenceDose
2006
Increase in Creatinine and Cardiovascular Risk in Patients with Systolic Dysfunction after Myocardial Infarction
Jose P, Skali H, Anavekar N, Tomson C, Krumholz HM, Rouleau JL, Moye L, Pfeffer MA, Solomon SD, Investigators F. Increase in Creatinine and Cardiovascular Risk in Patients with Systolic Dysfunction after Myocardial Infarction. Journal Of The American Society Of Nephrology 2006, 17: 2886-2891. PMID: 16928807, DOI: 10.1681/asn.2006010063.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionMyocardial infarctionCaptopril groupCardiovascular riskRenal functionSerum creatininePotent independent risk factorVentricular Enlargement (SAVE) trialBaseline renal functionHeart failure populationComposite end pointIndependent risk factorSerum creatinine measurementsBaseline creatinineCardiovascular deathCardiovascular morbidityPlacebo groupRenal dysfunctionSystolic dysfunctionVentricular dysfunctionAdverse eventsPrognostic importanceFailure populationTherapeutic choiceRisk factors
2004
Systolic Hypertension in Older Persons
Chaudhry SI, Krumholz HM, Foody JM. Systolic Hypertension in Older Persons. JAMA 2004, 292: 1074-1080. PMID: 15339901, DOI: 10.1001/jama.292.9.1074.BooksConceptsSystolic blood pressureSystolic hypertensionBlood pressureOlder personsOlder patientsClinical trialsBaseline systolic blood pressureTolerance of therapyJoint National CommitteeFirst-line therapyDiastolic blood pressureHigh blood pressureCalcium channel blockersRandomized clinical trialsTreatment of patientsEnglish-language literatureLarge-scale trialsSearch terms hypertensionAntihypertensive therapyCardiovascular riskThiazide diureticsDATA EXTRACTIONPatient preferencesSeventh ReportTerm hypertension